Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
- Author:
Doo Sun SIM
1
;
Myung Ho JEONG
;
Young Joon HONG
;
Ju Han KIM
;
Youngkeun AHN
;
Keun Ho PARK
;
Sun Ho HWANG
;
Dong Goo KANG
;
Seung Uk LEE
;
Joon Woo KIM
;
Jong Pil PARK
;
Jay Young RHEW
;
Sang Rok LEE
;
Jei Keon CHAE
;
Kyeong Ho YUN
;
Seok Kyu OH
;
Won You KANG
;
Su Hyun KIM
;
Jang Hyun CHO
Author Information
- Publication Type:Multicenter Study
- Keywords: Coronary Artery Disease; Drug-Eluting Stents; Percutaneous Coronary Intervention
- MeSH: Cohort Studies; Coronary Artery Disease; Drug-Eluting Stents; Follow-Up Studies; Heart; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Polymers; Prevalence; Propensity Score; Prospective Studies; Stents
- From:Chonnam Medical Journal 2018;54(1):55-62
- CountryRepublic of Korea
- Language:English
- Abstract: The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel percutaneous coronary intervention (PCI) were divided into 2 groups the ER group (n=288) and the ES group (n=200). The primary endpoint was a composite of major adverse cardiac events (MACE) consisting of death, myocardial infarction, and target vessel revascularization after 12 months. In all patients, the prevalence of diabetes was higher in the ER group (42.7% vs. 31.0%, p=0.009). The rate of post-PCI Thrombolysis in Myocardial Infarction flow grade 3 was higher in the ER group (100.0% vs. 98.0%, p=0.028). There were no between-group differences in the in-hospital, 1-month and 12-month clinical outcomes. In the propensity score matched cohort (n=200 in each group), no differences were observed in the baseline and procedural characteristics. There were no statistical differences in the rates of in-hospital, 1-month and 12-month events (12-month MACE in the ER and ES groups: 6.0% vs. 3.5%, p=0.240, respectively). The safety and efficacy of both versions of ZES were comparable in patients with multivessel disease during a 12-month clinical follow-up.
